CA2951049C - Peptide-drug conjugates - Google Patents

Peptide-drug conjugates Download PDF

Info

Publication number
CA2951049C
CA2951049C CA2951049A CA2951049A CA2951049C CA 2951049 C CA2951049 C CA 2951049C CA 2951049 A CA2951049 A CA 2951049A CA 2951049 A CA2951049 A CA 2951049A CA 2951049 C CA2951049 C CA 2951049C
Authority
CA
Canada
Prior art keywords
ala
cancer
peptide
asn
pabc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2951049A
Other languages
English (en)
French (fr)
Other versions
CA2951049A1 (en
Inventor
Shaosong Chu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiaray Pharmaceuticals Inc
Original Assignee
Jiaray Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiaray Pharmaceuticals Inc filed Critical Jiaray Pharmaceuticals Inc
Publication of CA2951049A1 publication Critical patent/CA2951049A1/en
Application granted granted Critical
Publication of CA2951049C publication Critical patent/CA2951049C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2951049A 2014-06-03 2015-06-01 Peptide-drug conjugates Active CA2951049C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462007159P 2014-06-03 2014-06-03
US62/007,159 2014-06-03
PCT/US2015/033509 WO2015187540A1 (en) 2014-06-03 2015-06-01 Peptide-drug conjugates

Publications (2)

Publication Number Publication Date
CA2951049A1 CA2951049A1 (en) 2015-12-10
CA2951049C true CA2951049C (en) 2023-01-03

Family

ID=54700553

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2951049A Active CA2951049C (en) 2014-06-03 2015-06-01 Peptide-drug conjugates

Country Status (9)

Country Link
US (2) US9579317B2 (enExample)
EP (1) EP3152223B1 (enExample)
JP (2) JP6539729B2 (enExample)
CN (1) CN106456799B (enExample)
AU (1) AU2015270924B2 (enExample)
CA (1) CA2951049C (enExample)
ES (1) ES2857192T3 (enExample)
MA (1) MA40030A (enExample)
WO (1) WO2015187540A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2958495C (en) 2014-08-22 2023-04-18 Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. Small molecule conjugates specifically activated in tumor microenvironment for targeting and use thereof
JP7251981B2 (ja) * 2016-03-24 2023-04-04 バイエル ファーマ アクチエンゲゼルシャフト 酵素開裂基を有する細胞毒性活性剤のプロドラッグ
CN107375288B (zh) 2016-05-16 2019-08-23 博瑞生物医药（苏州）股份有限公司 多臂的聚合靶向抗癌偶联物
US12059472B2 (en) 2016-12-21 2024-08-13 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
CN108314703B (zh) * 2017-01-17 2022-02-01 亚飞（上海）生物医药科技有限公司 分子定点靶向和激活的激酶抑制剂的制备和用途
US11191843B2 (en) 2017-04-21 2021-12-07 Brightgene Bio-Medical Technology Co., Ltd. Multi-arm targeting anti-cancer conjugate
CN107670048B (zh) * 2017-08-30 2019-04-26 南京明臻医药科技有限公司 具有协同抗癌活性的中间体药物和聚乙二醇偶联协同抗癌药物、及其制备方法和应用
EP3908307A4 (en) * 2019-01-07 2022-10-12 Cenna Biosciences Inc. NOVEL PEPTIDES AND USES THEREOF
WO2020206358A1 (en) * 2019-04-05 2020-10-08 Prolynx Llc Improved conjugation linkers
WO2020241445A1 (ja) * 2019-05-24 2020-12-03 学校法人慈恵大学 薬剤、肺胞の洗浄用の薬液、及び、ネブライザー
KR20230141754A (ko) * 2020-10-30 2023-10-10 아박타 라이프 사이언시스 리미티드 Fap-활성화 혈청 반감기 연장된 치료 접합체
KR20230141755A (ko) * 2020-10-30 2023-10-10 아박타 라이프 사이언시스 리미티드 효소 활성화 혈청 반감기 연장된 치료 접합체
CN115850288B (zh) * 2022-11-25 2025-03-21 中科帅天医药(深圳)有限公司 一种丝裂霉素c前体药物及其制备方法和应用
CN120835795A (zh) * 2023-03-09 2025-10-24 拜斯科技术开发有限公司 双环毒素偶联物及其中间体的合成
CN117683079B (zh) * 2023-12-12 2025-04-04 九洲药业(杭州)有限公司 一种抗体偶联药物连接子的固相合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3803223A (en) * 1970-07-20 1974-04-09 Searle & Co 3-amino-n-substituted succinamic acids and intermediates thereto
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
KR20020082227A (ko) * 2000-02-24 2002-10-30 제넨테크, 인크. 카스파제 활성화 전구약물 요법
US8314060B2 (en) 2000-09-05 2012-11-20 Biosight Ltd. Peptide conjugated anti-cancer prodrugs
CA2536357A1 (en) 2003-05-29 2004-12-23 The Scripps Research Institute Targeted delivery to legumain-expressing cells
CN101374856A (zh) * 2005-11-29 2009-02-25 斯克里普斯研究学院 抑制肿瘤细胞浸润、转移和血管生成
EP2266964B1 (en) * 2009-06-22 2013-01-09 KTB Tumorforschungsgesellschaft mbH Acid-labile trigger units
US8394922B2 (en) * 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
US20140057844A1 (en) 2010-12-03 2014-02-27 Tin Tin Su Chemical entities and therapeutic uses thereof

Also Published As

Publication number Publication date
JP2019189623A (ja) 2019-10-31
ES2857192T3 (es) 2021-09-28
US20150343083A1 (en) 2015-12-03
AU2015270924B2 (en) 2019-09-12
JP2017521486A (ja) 2017-08-03
EP3152223A4 (en) 2017-12-20
CN106456799A (zh) 2017-02-22
CN106456799B (zh) 2020-05-22
US20170232023A1 (en) 2017-08-17
EP3152223A1 (en) 2017-04-12
EP3152223B1 (en) 2020-11-25
CA2951049A1 (en) 2015-12-10
US9579317B2 (en) 2017-02-28
AU2015270924A1 (en) 2016-12-15
WO2015187540A1 (en) 2015-12-10
MA40030A (fr) 2015-12-10
JP6539729B2 (ja) 2019-07-03

Similar Documents

Publication Publication Date Title
CA2951049C (en) Peptide-drug conjugates
WO2015106599A1 (en) Conjugates and compositions for drug delivery
ES2198421T3 (es) Derivados de la camptotecina unidos a polimeros.
EP0624377A2 (en) Lysosomal enzyme-cleavable antitumor drug conjugates
AU2018265333C1 (en) Peptidic linkers and cryptophycin conjugates, useful in therapy, and their preparation
CN103044521B (zh) 天冬氨酸酶靶向激活的阿霉素衍生物、其制备方法和用途
WO2024012569A1 (en) Linkers, conjugates and applications thereof
US11319341B2 (en) Immune-stimulating soluble doxorubicin-conjugated complex
RS51169B (sr) Kamptotecini konjugirani na položaju 7 sa cikličnim peptidima kao citostatička sredstva
EP4217007B1 (en) Peptidic conjugates of sn38 useful in the treatment of cancer
US20020173468A1 (en) Modified cytostatic agents
CA2754846C (en) Prostate-specific antigen cleavable prodrugs
HK40097010B (en) Peptidic conjugates of sn38 useful in the treatment of cancer
HK40097010A (en) Peptidic conjugates of sn38 useful in the treatment of cancer
KR20010012558A (ko) 20(ｓ) 캄프토테신 당결합체

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200311

EEER Examination request

Effective date: 20200311

EEER Examination request

Effective date: 20200311

EEER Examination request

Effective date: 20200311

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240724

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240727

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250409

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250409